Bill Burkoth

Biography

 Bill is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently serves on the board of directors of Biodesy, NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and BBI Financial Gestão de Recursos (Rio, Brazil). Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

Research Interest

 Pharmaceuticals and at IntraBiotics